304 related articles for article (PubMed ID: 27287723)
1. The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations.
Meeth K; Wang JX; Micevic G; Damsky W; Bosenberg MW
Pigment Cell Melanoma Res; 2016 Sep; 29(5):590-7. PubMed ID: 27287723
[TBL] [Abstract][Full Text] [Related]
2. Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.
Song C; Piva M; Sun L; Hong A; Moriceau G; Kong X; Zhang H; Lomeli S; Qian J; Yu CC; Damoiseaux R; Kelley MC; Dahlman KB; Scumpia PO; Sosman JA; Johnson DB; Ribas A; Hugo W; Lo RS
Cancer Discov; 2017 Nov; 7(11):1248-1265. PubMed ID: 28864476
[TBL] [Abstract][Full Text] [Related]
3. Ascophyllan functions as an adjuvant to promote anti-cancer effect by dendritic cell activation.
Zhang W; Okimura T; Xu L; Zhang L; Oda T; Kwak M; Yu Q; Jin JO
Oncotarget; 2016 Apr; 7(15):19284-98. PubMed ID: 27008707
[TBL] [Abstract][Full Text] [Related]
4. A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model.
Bellmann L; Cappellano G; Schachtl-Riess JF; Prokopi A; Seretis A; Ortner D; Tripp CH; Brinckerhoff CE; Mullins DW; Stoitzner P
Int J Cancer; 2020 Mar; 146(5):1409-1420. PubMed ID: 31702822
[TBL] [Abstract][Full Text] [Related]
5. N-propionyl-4-S-cysteaminylphenol induces apoptosis in B16F1 cells and mediates tumor-specific T-cell immune responses in a mouse melanoma model.
Ishii-Osai Y; Yamashita T; Tamura Y; Sato N; Ito A; Honda H; Wakamatsu K; Ito S; Nakayama E; Okura M; Jimbow K
J Dermatol Sci; 2012 Jul; 67(1):51-60. PubMed ID: 22622238
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma.
Forte G; Sorrentino R; Montinaro A; Luciano A; Adcock IM; Maiolino P; Arra C; Cicala C; Pinto A; Morello S
J Immunol; 2012 Sep; 189(5):2226-33. PubMed ID: 22826317
[TBL] [Abstract][Full Text] [Related]
7. EGFR-TKI acquired resistance in lung cancers harboring EGFR mutations in immunocompetent C57BL/6J mice.
Higo H; Ohashi K; Makimoto G; Nishii K; Kudo K; Kayatani H; Watanabe H; Kano H; Ninomiya K; Hotta K; Maeda Y; Kiura K
Lung Cancer; 2019 Oct; 136():86-93. PubMed ID: 31470227
[TBL] [Abstract][Full Text] [Related]
8. Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumors.
Combest AJ; Roberts PJ; Dillon PM; Sandison K; Hanna SK; Ross C; Habibi S; Zamboni B; Müller M; Brunner M; Sharpless NE; Zamboni WC
Oncologist; 2012; 17(10):1303-16. PubMed ID: 22993143
[TBL] [Abstract][Full Text] [Related]
9. Immunity to B16 melanoma in mice immunized with IL-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens.
Kim TS; Russell SJ; Collins MK; Cohen EP
Int J Cancer; 1992 May; 51(2):283-9. PubMed ID: 1533203
[TBL] [Abstract][Full Text] [Related]
10. Poorly metastatic tumor cell variants as primary targets of syngeneic antibody responses against murine melanoma.
Parratto NP; Odebralski JM; Kimura AK
Cancer Res; 1989 Jul; 49(14):3722-8. PubMed ID: 2736512
[TBL] [Abstract][Full Text] [Related]
11. Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors.
Kuczynski EA; Krueger J; Chow A; Xu P; Man S; Sundaravadanam Y; Miller JK; Krzyzanowski PM; Kerbel RS
Mol Cancer Ther; 2018 Apr; 17(4):869-882. PubMed ID: 29483207
[TBL] [Abstract][Full Text] [Related]
12. Whole recombinant yeast vaccine induces antitumor immunity and improves survival in a genetically engineered mouse model of melanoma.
Tanaka A; Jensen JD; Prado R; Riemann H; Shellman YG; Norris DA; Chin L; Yee C; Fujita M
Gene Ther; 2011 Aug; 18(8):827-34. PubMed ID: 21390072
[TBL] [Abstract][Full Text] [Related]
13. MYC oncogene is associated with suppression of tumor immunity and targeting Myc induces tumor cell immunogenicity for therapeutic whole cell vaccination.
Wu X; Nelson M; Basu M; Srinivasan P; Lazarski C; Zhang P; Zheng P; Sandler AD
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33757986
[TBL] [Abstract][Full Text] [Related]
14. Multidrug resistance decreases with mutations of melanosomal regulatory genes.
Xie T; Nguyen T; Hupe M; Wei ML
Cancer Res; 2009 Feb; 69(3):992-9. PubMed ID: 19155314
[TBL] [Abstract][Full Text] [Related]
15. Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth.
Guan X; LaPak KM; Hennessey RC; Yu CY; Shakya R; Zhang J; Burd CE
Mol Cancer Res; 2017 Mar; 15(3):237-249. PubMed ID: 28039358
[TBL] [Abstract][Full Text] [Related]
16. The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma.
Cho JH; Lee HJ; Ko HJ; Yoon BI; Choe J; Kim KC; Hahn TW; Han JA; Choi SS; Jung YM; Lee KH; Lee YS; Jung YJ
Oncotarget; 2017 Apr; 8(15):24932-24948. PubMed ID: 28212561
[TBL] [Abstract][Full Text] [Related]
17.
Li M; Ma Y; Zhong Y; Liu Q; Chen C; Qiang L; Wang X
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037113
[TBL] [Abstract][Full Text] [Related]
18. Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma.
Iannone R; Miele L; Maiolino P; Pinto A; Morello S
Neoplasia; 2013 Dec; 15(12):1400-9. PubMed ID: 24403862
[TBL] [Abstract][Full Text] [Related]
19. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells.
Kong LY; Abou-Ghazal MK; Wei J; Chakraborty A; Sun W; Qiao W; Fuller GN; Fokt I; Grimm EA; Schmittling RJ; Archer GE; Sampson JH; Priebe W; Heimberger AB
Clin Cancer Res; 2008 Sep; 14(18):5759-68. PubMed ID: 18794085
[TBL] [Abstract][Full Text] [Related]
20. Blockade of integrin β3 signals to reverse the stem-like phenotype and drug resistance in melanoma.
Zhu X; Tao X; Lu W; Ding Y; Tang Y
Cancer Chemother Pharmacol; 2019 Apr; 83(4):615-624. PubMed ID: 30627776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
